Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the administration of a poorly-absorbable
antibiotic (rifaximin) for the first three months after liver transplant will reduce the
amount of fibrosis (or scarring of the liver) in liver transplant patients with recurrent
hepatitis C virus (HCV) by lowering serum lipopolysaccharide (LPS), a protein in blood that
comes from the bacteria in intestines and may cause scarring in the liver.
Approximately 60 subjects will participate in this study. Subjects will be part of the study
for approximately 1 year post transplant.